Lotte Biologics to Attend Consecutive Global Bio Events in the Second Half of the Year

Lotte Biologics announced on September 22 that it will participate in a series of international bio conferences held around the world-including in Asia, Europe, and the United States-from next month through November, in order to showcase its competitiveness as a global CDMO (Contract Development and Manufacturing Organization).

Starting with "Bio Japan 2025" in Yokohama, Japan, from October 8 to 10, Lotte Biologics will consecutively attend three major events: "CPHI Worldwide," the global pharmaceutical exhibition in Frankfurt, Germany, from October 28 to 30, and "World ADC San Diego 2025" in San Diego, United States, from November 3 to 6.

Lotte Biologics plans to further strengthen its global partnerships by highlighting two key strategies: the advantages of its "Dual Site" system and its "proven quality competitiveness." The Syracuse Bio Campus has already announced three contract wins this year, while the first plant of the Songdo Bio Campus, scheduled to begin full-scale operations in 2027, held a topping-out ceremony on September 9-demonstrating the tangible benefits of the dual site approach. In addition, the company plans to emphasize its position as the optimal partner for resolving supply chain instability, in line with the recent reshoring trend in the United States.

"Bio Japan," which Lotte Biologics will attend next month, is Asia's largest bio event, launched in 1986, and supports exhibitions, seminars, and partnering for participating companies. Lotte Biologics will operate a standalone exhibition booth more than twice the size of last year's, offering company introductions for visitors and partnering meetings with potential clients. On the third day of the event, October 10, CEO Park James will deliver a seminar presentation titled "Pharma's Next Frontier: CDMO Strategies and the Growing Market for Next-Gen ADCs," highlighting the company's market competitiveness.

"CPHI Worldwide" is the world's largest pharmaceutical and biopharmaceutical exhibition, held annually in Europe. At this event, Lotte Biologics will promote the capabilities of the ADC production facility at the Syracuse Bio Campus and highlight the synergy with the Songdo Bio Campus through an "In Booth Presentation." Additionally, the company will host a dart game event themed around ADCs targeting cancer cell antigens, further expanding engagement with both visitors and potential clients through a variety of interactive activities.

The "World ADC," taking place in November, is a globally renowned event in the ADC field, where pharmaceutical and biotech companies and experts from around the world gather to share the latest research results and technology trends. In particular, during the presentation sessions, Lotte Biologics will highlight the strengths of its antibody-drug conjugate (ADC) platform and emphasize its technological competitiveness as a proven global ADC CDMO.

Lotte Biologics has also maintained a strong presence at various global bio conferences in the first half of this year, including the "JP Morgan Healthcare Conference," "World ADC Asia," and "Bio USA." Notably, at "Bio USA" in June, the company announced new contract wins for antibody drug CDMO services with global bio companies, further solidifying its position as a global CDMO at international bio events.

A Lotte Biologics representative stated, "We plan to actively promote Lotte Biologics' proven capabilities at various international events," adding, "We will continue to strengthen our global competitiveness through proactive partnering in the second half of the year."

This content was produced with the assistance of AI translation services.